ATXS
Astria TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ATXS Profile
Astria Therapeutics, Inc.
A company that develops novel therapeutics for the rare and niche allergic and immunological diseases
75 State Street, Suite 1400, Boston, Massachusetts 02109
--
Astria Therapeutics, Inc., was founded in Delaware on June 26, 2008 and is headquartered in Cambridge, Massachusetts.
The company is a biopharmaceutical company focused on the discovery, development and commercialization of new therapies. The company's mission is to bring hope to patients and families affected by rare and niche allergic and immune diseases through life-changing therapies. The company's lead product candidate is STAR-0215, a potentially best-in-class monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. Based on the data generated so far and the existing HAE treatment profile, STAR-0215 has the potential to be the most patient-friendly chronic treatment for HAE.
